GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Forward PE Ratio

Biomark Diagnostics (Biomark Diagnostics) Forward PE Ratio : 0.00 (As of May. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics Forward PE Ratio?

Biomark Diagnostics's Forward PE Ratio for today is 0.00.

Biomark Diagnostics's PE Ratio without NRI for today is 0.00.

Biomark Diagnostics's PE Ratio for today is 0.00.


Biomark Diagnostics Forward PE Ratio Historical Data

The historical data trend for Biomark Diagnostics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Forward PE Ratio Chart

Biomark Diagnostics Annual Data
Trend
Forward PE Ratio

Biomark Diagnostics Quarterly Data
Forward PE Ratio

Competitive Comparison of Biomark Diagnostics's Forward PE Ratio

For the Diagnostics & Research subindustry, Biomark Diagnostics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Forward PE Ratio falls into.



Biomark Diagnostics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Biomark Diagnostics  (OTCPK:BMKDF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Biomark Diagnostics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines